Gleevec's latest approval is for pediatric cancer

(HealthDay)—The anti-cancer drug Gleevec (imatinib) has received new U.S. Food and Drug Administration approval to treat the most common type of pediatric cancer, affecting some 2,900 children each year, the agency said Friday.

Philadelphia chromosome positive (ALL) progresses rapidly if left untreated. Gleevec, among a class of drugs called , blocks proteins that promote development of cancer cells, the FDA said in a news release.

The most common side effects observed in pediatric testing included infection and a decrease in white blood cells and blood platelets.

Gleevec was first approved in 2001 to treat a form of , and has since been approved to treat several other conditions. The drug is marketed by Novartis, based in East Hanover, N.J.

More information: To learn more about Gleevec, visit the U.S. National Cancer Institute.

add to favorites email to friend print save as pdf

Related Stories

Iclusig approved for rare leukemias

Dec 16, 2012

(HealthDay)—Iclusig (ponatinib) has been approved by the U.S. Food and Drug Administration to treat two rare forms of leukemia..

Marqibo approved for ph- acute lymphoblastic leukemia

Aug 10, 2012

(HealthDay) -- Marqibo (vincristine sulfate liposome injection) has been approved by the U.S. Food and Drug Administration to treat adults with Philadelphia chromosome negative acute lymphoblastic leukemia ...

Marqibo approved for rare leukemia

Aug 10, 2012

(HealthDay) -- Marqibo (vincristine sulfate liposome injection) has been approved by the U.S. Food and Drug Administration to treat adults with a rare form of blood and bone marrow cancer, Philadelphia chromosome negative ...

Synribo approved to treat rare leukemia

Oct 26, 2012

(HealthDay)—Synribo (omacetaxine mepesuccinate) has been approved by the U.S. Food and Drug Administration to treat a rare blood and bone marrow disease called chronic myelogenous leukemia (CML).

Recommended for you

ACG: Recent increase in incidence of young-onset CRC

11 hours ago

(HealthDay)—The incidence of young-onset colorectal cancer (CRC) is increasing, and the disease is more aggressive pathologically. These findings are being presented at the annual meeting of the American ...

User comments